Compare DHT & SUPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DHT | SUPN |
|---|---|---|
| Founded | 2005 | 2005 |
| Country | Bermuda | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 2.8B |
| IPO Year | 2005 | 2010 |
| Metric | DHT | SUPN |
|---|---|---|
| Price | $17.47 | $48.15 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | $19.33 | ★ $61.60 |
| AVG Volume (30 Days) | ★ 3.9M | 916.2K |
| Earning Date | 05-05-2026 | 05-05-2026 |
| Dividend Yield | ★ 5.36% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $392,755,000.00 |
| Revenue This Year | $8.85 | $22.70 |
| Revenue Next Year | N/A | $19.14 |
| P/E Ratio | $12.73 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $10.61 | $32.21 |
| 52 Week High | $20.55 | $59.68 |
| Indicator | DHT | SUPN |
|---|---|---|
| Relative Strength Index (RSI) | 48.28 | 54.04 |
| Support Level | $17.14 | $47.48 |
| Resistance Level | $18.80 | $52.24 |
| Average True Range (ATR) | 0.71 | 1.58 |
| MACD | 0.02 | 0.10 |
| Stochastic Oscillator | 48.34 | 38.42 |
DHT Holdings Inc is a crude oil tanker company. The company's primary business is operating a fleet of crude oil tankers, with a secondary activity of providing technical management services. Its fleet trades internationally and consists of VLCC crude oil tankers. The group generates revenues from time charter and spot market operations. It operates vessels through its subsidiary management companies in Monaco, Norway, Singapore, and India. The company generates the majority of its revenue from Voyage charter revenues.
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, Osmolex ER, and others.